Index to volume 23

Index to Volume

23

Abken, H., Hombach, A., Heuser, C., Sircar, R., Pohl, C. and Reinhold, U., Chimeric T-cell receptors: highly specific tools to target cytotoxic T-lymphocytes to tumour cells . . . . . . . . . . . . . . . Ardiet,

97

C., see Freyer, G.

Auerbach,

L., see Obwegeser,

R.

Beijnen,

J. H., see Crul, M.

Beijnen,

J. H., see Meerum

Beijnen,

J. H., see Westerman,

Terwogt,

J. M.

A. M.

Bezwoda, W. R., The treatment of disseminated malignant melanoma with special reference to the role of interferons, vinca alkaloids and tamoxifen . . . . . . . . . . . . . . . . . . . . . . . Brock, C., see Newlands, Cleton,

17

E. S.

F. J., see Weijl, N. I.

Crul, M., Schellens, J. H. M., Beijnen, J. H. and Maliepaard, M., Cisplatin resistance and DNA repair . . . . . . . . . . . . . . . . . Fisher, P. M. and Hancock, B. W., Gestational their treatment . . . . . . . . . .

.

trophoblastic . . . .

.

diseases and . . . . .

Freyer, G., Ligneau, B., Tranchand, B., Ardiet, C., Serre-Debeauvais, F. and Trillet-Lenoir, V., Pharmacokinetic studies in cancer chemotherapy: usefulness in clinical practice . . . . . . . . . . . . . . . Guchelaar,

H.-J., see Vermes,

B. W., see Fisher, P. M.

Hawkins,

N. J., see Ward, R. L.

A., see Abken,

Jekunen,

A. P. and Kairemo,

Kairemo,

K. J. A.. see Jekunen,

Kok, T. C., Chemotherapy Koopmans,

153

H.

Hombach,

Kerr, D. J., see Midgley,

1

A.

Hancock,

Heuser, C., see Abken,

.

341

H. K. J. A., Inhibition

of malignant

angiogenesis

263

A. P.

R. S. in oesophageal

R. P., see Vermes,

A.

cancer

.

.

.

.

.

.

.

.

65

INDEX

ii

Kubista,

E., see Obwegeser,

Ligneau,

B., see Freyer, G.

Maliepaard,

R.

M., see Crul, M.

Meerum Beijnen,

Terwogt, J. M., Nuijen, B., Ten Bokkel Huinink, J. H., Alternative formulations of paclitaxel . . .

Midgley,

R. S. and Kerr, D. J., Adjuvant

Miller, W. R., Aromatase

of colorectal

Newlands, E. S., Stevens, M. F. G., Wedge, S. R., Wheelhouse, R. T. and Brock, C., Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials . . . . . . . . . . .

35

W. H., see Westerman,

V., see Vermylen,

Nuijen,

B., see Meerum

.

.

. .

P. Terwogt,

J. M. aspects of . . . . .

289

S., see Weijl, N. I.

Pohl, C., see Abken, Reinhold,

H.

U., see Abken,

Rodenhuis,

H.

S., see Westerman,

Roufosse,

C., see Vermylen,

Schellens,

J. H. M., see Crul, M.

Sculier, J.-P., see Vermylen, Serre-Debeauvais,

A. M.

P.

P.

F., see Freyer, G.

Sircar, R., see Abken, Smith,

.

A. M.

Obwegeser, R., Auerbach, L. and Kubista, E., Gynaecological tamoxifen treatment in breast cancer patients . . . . . Osanto,

.

135 171

Ninane,

and breast cancer

cancer

87

.

Moolenaar,

inhibitors

treatment

W. W. and . . . . .

H.

G. M., see Ward, R. L.

Stevens,

M. F. G., see Newlands,

Ten Bokkel Huinink,

E. S.

W. W., see Meerum

Terwogt,

J. M.

Thomas, A. L. and Wall, P. J., Cytotoxic dose-response small cell lung cancer . . . . . . . . . . . . Tranchand, Trillet-Lenoir,

in .

191

of a . .

321

C., Ninane, V. and Sculier, J.-P., Biology of lesions . . . . . . . . . . . . . . .

241

.

relationships . . . .

B., see Freyer, G. V., see Freyer, G.

Vermes, A., Guchelaar, H.-J. and Koopmans, R. P., Individualization cancer therapy based on cytochrome P450 polymorphism: pharmacogenetic approach . . . . . . . . . . . . . , . Vermylen, pulmonary

.

P., Roufosse, preneoplastic

iii

INDEX

Ward, R. L., Hawkins, N. J. and Smith, G. M., Unconjugated for cancer therapy: lessons from the clinic . . . . . . Wedge,

S. R., see Newlands,

.

antibodies . . . .

E. S.

Weijl, N. I., Cleton, F. J. and Osanto, S., Free radicals and antioxidants in chemotherapy-induced toxicity . . . . . . . . . . . . . Westerman, A. M., Beijnen, J. H., Moolenaar, W. H. and Rodenhuis, Growth factors in human ovarian cancer . . . . . . . . . . Wheelhouse,

R. T., see Newlands,

Wall, P. J., see Thomas,

A. L.

305

E. S.

.

.

209

S., .

113